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Histological diagnostic criterion for chronic 
endometritis based on the clinical outcome
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Akie Takebayashi1,3, Akiko Takashima1, Tsukuru Amano1, Shunichiro Tsuji1, Shoji Kaku1, Ryoji Kushima4 
and Takashi Murakami1
Abstract 
Background: The diagnostic criteria of chronic endometritis remain controversial in the treatment for infertile 
patients.
Methods: A prospective observational study was conducted in a single university from June 2014 to September 
2017. Patients who underwent single frozen-thawed blastocyst transfer with a hormone replacement cycle after 
histological examination for the presence of chronic endometritis were enrolled. Four criteria were used to define 
chronic endometritis according to the number of plasma cells in the same group of patients: 1 or more (≥ 1) plasma 
cells, 2 or more (≥ 2), 3 or more (≥ 3), or 5 or more (≥ 5) in 10 high-power fields. Pregnancy rates, live birth rates, and 
miscarriage rates of the non-chronic endometritis and the chronic endometritis groups defined with each criterion 
were calculated. A logistic regression analysis was performed for live births using eight explanatory variables (seven 
infertility factors and chronic endometritis). A receiver operating characteristic curve was drawn and the optimal cut-
off value was calculated.
Results: A total of 69 patients were registered and 53 patients were finally analyzed after exclusion. When the diag-
nostic criterion was designated as the presence of ≥ 1 plasma cell in the endometrial stroma per 10 high-power fields, 
the pregnancy rate, live birth rate, and miscarriage rate were 63.0% vs. 30.8%, 51.9% vs. 7.7%, and 17.7% vs. 75% in the 
non-chronic and chronic endometritis groups, respectively. This criterion resulted in the highest pregnancy and live 
birth rates among the non-chronic endometritis and the smallest P values for the pregnancy rates, live birth rates, 
and miscarriage rates between the non-chronic and chronic endometritis groups. In the logistic regression analysis, 
chronic endometritis was an explanatory variable negatively affecting the objective variable of live birth only when 
chronic endometritis was diagnosed with ≥ 1 or ≥ 2 plasma cells per 10 high-power fields. The optimal cut-off value 
was obtained when one or more plasma cells were found in 10 high-power fields (sensitivity 87.5%, specificity 64.9%).
Conclusions: Chronic endometritis should be diagnosed as the presence of ≥ 1 plasma cells in 10 high-power fields. 
According to this diagnostic criterion, chronic endometritis adversely affected the pregnancy rate and the live birth 
rate.
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Background
Chronic endometritis (CE) is defined as slight inflam-
mation of the endometrium and is generally agreed that 
the presence of plasma cells within the endometrial 
stroma is the most useful histologic criterion for diag-
nosis [1–7]. Although patients with CE have no or subtle 
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clinical symptoms, and no clinical significance has yet 
been found, there have recently been many reports that 
show its relationship with infertility and implantation 
failure [4, 8–16].
Epidemiologically, CE is recognized in 2.8% to 67.6%, 
from a very low frequency to a very high frequency, 
of patients with infertility and implantation failure [4, 
8, 11–16]. Bacterial infection is related to the cause of 
CE, because many cases of CE are cured by antibiotics 
[8–10, 15, 17–19]. It has been reported that the clini-
cal outcomes of in  vitro fertilized embryo transfer are 
improved when cure of CE is confirmed after administra-
tion of antibiotics for recurrent implantation failure (RIF) 
[10, 15, 17–19]. However, on the other hand, there have 
been reports that administration of antibiotics is ineffec-
tive, and reports that CE does not affect fertility at all [4, 
8]. Although the cause of the differences in the research 
results regarding the effects of CE on fertility may be due 
to different patient backgrounds and subjects in each 
study, we considered that the biggest problem is the dif-
ference in the diagnostic criteria for CE in each study. In 
many previous clinical studies of CE, the study subjects 
were patients with RIF, and the clinical outcomes were 
compared between the group cured with antibiotics and 
the persistent group [8–10, 13, 17]. However, antibiotics 
cannot be administered without establishing diagnostic 
criteria in advance. Thus, this methodology interferes 
with the determination of CE criteria depending on the 
clinical outcomes. Moreover, it is also difficult to purely 
evaluate the effect of CE on implantation when the con-
trol group is defined as patients with RIF without CE, 
since the pregnancy rate in patients with RIF will be 
lower in subsequent treatment cycles due to the pres-
ence of causes other than CE for implantation failure. 
For these reasons, there appear to be no uniform criteria 
based on clinical outcomes that are accepted worldwide.
Therefore, the present study examined whether or not 
the pregnancy rate, live birth rate and miscarriage rate 
differed between non-CE and CE when different diagnos-
tic criteria were set for the number of plasma cells in the 
endometrial stroma and the aim of the present study was 
to establish the most appropriate diagnostic criteria for 
CE.
Methods
This study was approved by the Ethics Committee of 
Shiga University of Medical Science (approved number 
2014-090). All clinical studies were conducted accord-
ing to the Declaration of Helsinki for Medical Research 
involving Human Subjects. Informed written consent 
was obtained from the participants. The patients were 
enrolled from June 2014 to September 2017.
As shown in Fig.  1, IVF or intracytoplasmic sperm 
injection was performed with a gonadotropin releasing 
hormone (GnRH) agonist protocol or a GnRH antagonist 






Evaluation of  the            
presence of plasma 
cells
Within 90 days
2. Stain the endometrium with CD138 antibody
The number of plasma cells in 10 HPF of the stromal area was 
evaluated with CD138 antibody staining of the endometrium.
1. Freeze blastocysts
4. Under the same hormone replacement protocol
3. Blastocyst transfer within 90 days of endometrial tissue sampling
Single frozen-thawed 
blastocyst transfer with 
hormone replacement cycle
Estradiol patch                    
+Dydrogesterone
Fig. 1 Protocol for the present study. Blastocysts were frozen following oocyte retrieval. Hysteroscopy and endometrial sampling were performed, 
and the number of plasma cells in 10 high-power fields (HPFs) of stromal area was evaluated with CD138 antibody staining of the endometrium. 
Single frozen-thawed blastocyst transfer was performed within 90 days after the endometrial evaluation with a hormone replacement cycle
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The subjects were patients under 41 years of age who 
agreed and underwent the in  vitro fertilization-embryo 
transfer (IVF-ET) protocol of our department, which 
includes routine hysteroscopy and local endometrial 
curettage (injury) before first frozen thawed embryo 
transfer.
The criteria for registration were set accordingly to 
a previous report with some modification [20]. Briefly, 
patients who had a history of RIF, recurrent pregnancy 
loss (RPL) or diseases suspected to cause implantation 
failure such as uterine malformation, multiple myoma, 
endometrial polyp, hydrosalpinx, adenomyosis with over 
a uterine wall > 2.5  cm thick or endometrial thinning 
(< 8 mm at implantation phase) detected by ultrasonog-
raphy [21–26], were not enrolled. Genetic disorders, 
endocrine diseases and autoimmune diseases were not 
enrolled either [27, 28] (Fig. 2a). RIF was defined as the 
failure of clinical pregnancy after 4 good quality embryo 
transfers, with at least three fresh or frozen IVF cycles, as 
per Coughlan et al. [29]. RPL was defined as the patient 
with 3 or more miscarriage [30].
After the identification of the ovulation day as reported 
previously [20], hysteroscopy and endometrial tissue 
collection were performed 5–9  days after ovulation. 
Whether endometrial macropolyps and uterine malfor-
mations were present was determined by hysteroscopy, 
and patients with these diseases were excluded from this 
study at that moment [23, 24] (Fig. 2a). Immediately after 
hysteroscopy, the tissue around the center of the anterior 
endometrium was collected with 4.5  J. A. M. W Type 
Uterine Curettes, and immunostaining of this sample 
for CD138 was performed, as reported previously [1, 20, 
31, 32]. One pathologist examined this tissue to deter-
mine how many plasma cells there were in 10 random 
HPFs (Olympus BX-41; hpf diameter = 0.55  mm; hpf 
area = 0.24  mm2) of the endometrial stromal area.
Before blastocyst transfer, patients again discussed 
their treatment options with doctors based on the find-
ings concerning the presence of plasma cells in the 
stroma of the endometrium, and when the patient 
wanted to add treatment that might modify the endome-
trial receptivity, such as the administration of antibiot-
ics [10, 13] or stimulated endometrium embryo transfer 
(SEET) [33], the patients were excluded from the study 
(Fig.  2a). Patients who wished to undergo two-embryo 
transfer were also excluded in order to limit the study’s 
treatment outcomes to single blastocyst transfer (Fig. 2a).
Blastocysts were transferred within 90  days of endo-
metrial tissue collection. An estradiol patch was started 
on days 2–3 of menstruation and increased gradually 
(Fig.  3). When the endometrial thickness reached 8 or 
more mm, oral administration of dydrorgesterone (DYD) 
was started (40  mg/day for patients weighing less than 
65 kg or 60 mg for those weighing 65 kg or more). Single 
frozen-thawed blastocyst transfer was performed six days 
after DYD administration, and a blood human chorionic 
gonadotropin (hCG) test was performed two weeks after 
blastocyst transfer. When hCG was detected, transvagi-
nal ultrasonography was performed within one week 
from that day, and the presence of a gestational sac in 
utero was considered to indicate pregnancy. When preg-
nancy was recognized, administration of these hormones 
was continued until 13 to 15 weeks of pregnancy. When 
the patients did not conceive or miscarriage resulted, 
their administration was discontinued as appropriate.
After obtaining the clinical outcomes of blastocyst 
transfer, the effect of the presence of plasma cell on the 
outcome was evaluated. We set four different diagnos-
tic criteria for the number of plasma cells existing in the 
stromal area per 10 HPFs and determined which crite-
ria matched the clinical data best. Diagnostic criteria 
were decided with reference to past reports. Four differ-
ent criteria for CE were used, according to the number 
of plasma cells: the first diagnostic criterion called for 
diagnosing CE when ≥ 1 plasma cell was found among 10 
HPFs and non-CE when no plasma cells were found [34]; 
the second diagnostic criterion called for diagnosing CE 
when ≥ 2 plasma cells were found among 10 HPFs and 
non-CE when ≤ 1 plasma cell was found [35]; the third 
diagnostic criterion called for diagnosing CE when ≥ 3 
plasma cells were found among 10 HPFs and non-CE 
when ≤ 2 plasma cells were found [35]; and the fourth 
diagnostic criterion called for diagnosing CE when ≥ 5 
plasma cells were found among 10 HPFs and non-CE 
when ≤ 4 plasma cells were found [11]. Pregnancy rates, 
live birth rates, and miscarriage rates were calculated in 
the non-CE and CE groups for each criterion and out-
comes were compared among four criteria.
A multivariate logistic regression analysis was per-
formed for eight explanatory variables, which included 
seven infertility factors (male factor, tubal factor, endo-
metriosis, ovarian factor, anti-sperm antibody-positive, 
fertilization failure, unexplained infertility) and CE, with 
respect to the objective variable of live birth to obtain 
factors that worked negatively for each criterion, as pre-
viously reported [20].
In addition, the sensitivity and specificity of the non-
CE group for live birth were calculated for each of these 
diagnostic criteria, and a receiver operating characteristic 
(ROC) curve was drawn from them. Based on the results, 
the area under the curve (AUC) was calculated, and the 
optimal cut-off values were determined.
Statistically analyses
The target number of participants in the present study 
was calculated based on a retrospective study reported by 
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Cicinelli et  al. [10]. According to their report, when CE 
was cured with antibiotics, the ongoing pregnancy rate 
was 60.8% (28/46), but when it persisted, the rate was 
13.3% (2/15); there was a significant difference between 
them. Based on these results, the number of patients 
required for enrollment was calculated using software 
provided by the Department of Biostatistics, Vanderbilt 
University (http://biost at.mc.vande rbilt .edu/wiki/Main/
Obtaining of frozen blastocyst
Hysteroscopy and endometrial 
sampling 
Embryo transfer
Excluded from the study if the following treatment was performed:
Administration of antibiotics to treat chronic endometritis
Stimulated endometrium embryo transfer (SEET)
Two-embryo transfer
Registered when meeting the following conditions:
Under 41 years of age
Agreed and underwent the in vitro fertilization-embryo transfer (IVF-
ET) protocol of our department, which includes routine hysteroscopy 
and local endometrial curettage (injury) before first frozen thawed 
embryo transfer.
Excluded from the registration (not registered) if the following disease was suffered:
Patients who had a history of recurrent implantation failure (RIF)
Recurrent pregnancy 
Uterine malformation, multiple myoma, endometrial polyp, hydrosalpinx,  
adenomyosis or endometrial thinning (<8 mm at implantation phase),
genetic disorders, endocrine and autoimmune diseases, 





based on the result of 
presence of plasma cell
a
Hysteroscopy and endometrial        69 
sampling 
Embryo transfer                              53
Registration 69
Discuss based on the result of        69 
presence of plasma cell
Excluded Antibiotic therapy 8
SEET 3
Two embryo transfer    5
Excluded 0
b
Fig. 2 a Flow of patient registration and exclusion. The subjects were patients under 41 years of age who agreed and underwent the in vitro 
fertilization-embryo transfer (IVF-ET) protocol of our department, which includes routine hysteroscopy and local endometrial curettage (injury) 
before first frozen thawed embryo transfer. Patients who had a history of RIF, recurrent pregnancy loss (RPL) or diseases suspected to cause 
implantation failure such as submucosal myoma, adenomyosis, uterine malformation, or endometrial thinning (< 8 mm at implantation phase) were 
not enrolled. Genetic disorders, endocrine diseases and autoimmune diseases were not enrolled either. The presence of endometrial macropolyps 
and uterine malformations were evaluated by hysteroscopy, and patients with these diseases were excluded from this study at that moment. Before 
blastocyst transfer, patients were discussed with doctors again with respect to the treatment options, based on the result of existence of plasma 
cell in the stroma of the endometrium, and when the patient wanted to add the treatment which might modify the endometrial receptivity such 
as administration of antibiotics, or stimulated endometrium embryo transfer, the patients were excluded from the study. The patients who want 
to treat two-embryo transfer were also excluded to limit the study of treatment outcomes for single blastocyst transfer. b The numbers of patients 
registered and excluded. Sixty-nine patients were recruited, and 16 patients were excluded. Fifty-seven patients were finally analyzed
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Power Sampl eSize ). In the section of Dichotomous, inde-
pendent, prospective, two proportion, and Fisher’s exact 
test were selected to measure the sample size. An α of 
0.05 was selected as the probability of falsely rejecting 
the null hypothesis, with 0.8 for power (the probability of 
always rejecting the null hypothesis if the null hypothesis 
is false in the statistical hypothesis test), 0.605 for P0 (the 
probability of the outcome for a control patient in pro-
spective studies), and 0.133 for P1 (the probability of the 
outcome in an experimental subject in prospective stud-
ies). When a value of 1 was selected for m (the ratio of 
control to experimental subjects for independent pro-
spective studies), it was calculated that enrollment of 19 
cases was necessary for each group. When m was chosen 
as 0.56, 0.36, 0.26 and 0.55, the number of cases required 
for control (non-CE) and CE became 26 and 15, 33 and 
12, 42 and 11, and 26 and 15, respectively.
Statistical analysis was performed using Graph Pad 
Prism 5 (GraphPad Software Inc., La Jolla, CA). The nor-
mality of the distribution of each dataset was analyzed 
using the Kolmogorov–Smirnov test, and then Student’s 
t-test or the non-parametric Mann–Whitney U test was 
used depending on the distribution pattern. The signifi-
cance of differences in pregnancy, live birth, and abortion 
rates between the non-CE and CE groups was examined 
using Fisher’s test. A significant difference was defined as 
a P value less than 0.05.
The SSPS statistics software program, version 25 (IBM, 
Chicago, IL, USA) was used for the multivariate logistic 
regression analysis. Odds ratios and P values were calcu-
lated. A significant difference was considered present at a 
P value < 0.05.
The JMP® software program (SAS Institute Inc. Cary, 
NC, USA) was used to depict the ROC curve.
Results
A total of 69 patients were registered (Fig. 2b). Of these, 
patients who wanted treatment with antibiotics, SEET, 
or two-embryo transfer, were excluded, and 53 patients 
were finally analyzed.
When CE was defined as ≥ 1 plasma cells in 10 
HPFs, there were 27 non-CE patients and 26 CE 
patients. When CE was defined as ≥ 2 plasma cells in 
10 HPFs, ≥ 3 plasma cells in 10 HPFs, or ≥ 5 plasma 
cells in 10 HPFs, the numbers of non-CE patients and 
CE patients were 34 and 19, 39 and 14, and 42 and 
11, respectively. These met the statistically required 
numbers.
When the diagnostic criterion for CE was the pres-
ence of ≥ 1 plasma cells in 10 HPFs, there were no 
differences between the two groups in patients’ back-
ground except parity (Table 1). The pregnancy rate, live 
birth rate, and miscarriage rate were 63.0% vs 30.8% 
(P = 0.028), 51.9% vs 7.7% (P = 0.0007), and 17.7% vs 
75% (P = 0.0099) in the non-CE and CE groups, respec-
tively. The pregnancy rate and live birth rate were sig-
nificantly lower in the CE group, and the miscarriage 
rate was significantly higher in the CE group.
When the diagnostic criterion for CE was the pres-
ence of ≥ 2 plasma cells in 10 HPFs, there were no 
differences between the two groups in patients’ back-
ground except age, parity, and the rate of tubal factor 
as infertility cause (Table  2). The pregnancy rate, live 
birth rate, and miscarriage rate were 58.8% vs 26.3% 
(P = 0.043), 44.1% vs 5.3% (P = 0.0041), and 25% vs 80% 
(P = 0.04) in the non-CE and CE groups, respectively. 
The pregnancy rate and live birth rate were significantly 
lower in the CE group, and the miscarriage rate was 
significantly higher in the CE group.
Multiple E2 patches (0.72 mg)/2
days 
Dydrogesterone
40 mg/day <65 kg







Fig. 3 Protocol of single frozen-thawed blastocyst transfer with a hormone replacement cycle. Multiple estradiol patches are started on days 2–3 
of menstruation and increased gradually. When the endometrial thickness reaches 8 or more mm, oral administration of dydrogesterone (DYD) is 
started. Single blastocyst transfer is done 6 days after DYD is started
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When the diagnostic criterion for CE was the presence 
of ≥ 3 plasma cells in 10 HPFs, there were no differences 
between the two groups in patients’ background except 
age, gravidity, and parity (Table  3). The pregnancy rate, 
live birth rate, and miscarriage rate were 53.9% vs 28.6% 
(P = 0.13), 38.5% vs 7.1% (P = 0.041), and 28.6% vs 75% 
(P = 0.12) in the non-CE and CE groups, respectively. The 
live birth rate was significantly lower in the CE group, but 
there were no differences in the pregnancy rate and the 
miscarriage rate between the groups.
When the diagnostic criterion for CE was the presence 
of ≥ 5 plasma cells in 10 HPFs, there were no differences 
between the two groups in patients’ background except 
age and parity (Table  4). The pregnancy rate, live birth 
rate, and miscarriage rate were 50% vs 36.4% (P = 0.51), 
35.7% vs 9.1% (P = 0.14), and 28.6% vs 75% (P = 0.12) in 
the non-CE and CE groups, respectively. There were no 
significant differences in the pregnancy rate, live birth 
rate, and miscarriage rate.
According to the multivariate logistic regression analy-
sis, CE was the only explanatory variable that negatively 
affected the objective variables of live birth when CE 
was diagnosed with the diagnostic criteria of ≥ 1 or ≥ 2 
plasma cells per 10 HPFs, although no independent vari-
able was detected as a negative factor when CE was diag-
nosed using other criteria. The odds ratio (P value, [95% 
confidence interval]) for live birth was 0.081 (P = 0.016, 
[0.01–0.625]) when CE was diagnosed with ≥ 1 plasma 
cell per 10 HPFs and 0.064 (P = 0.044, [0.004–0.93) when 
CE was diagnosed with ≥ 2 plasma cells per 10 HPFs 
(Table 5).
The AUC of the ROC curve was 0.785. The optimal cut-
off value was obtained when ≥ 1 plasma cell was found 
among 10 HPFs (sensitivity of 87.5% and specificity of 
64.9%) (Fig. 4).
Discussion
In the present study, diagnostic criteria for CE using 
endometrial specimens were prospectively evaluated 
based on clinical outcomes in patients undergoing a uni-
form program of single blastocyst transfer in hormone 
replacement cycles after excluding participants with 
RIF, RPL, and diseases suspected to cause implantation 
failure when participants were enrolled. The pregnancy 
Table 1 Patients’ characteristics and  clinical outcomes 
when CE was defined as ≥ 1 PCs in 10 HPFs 
CE chronic endometritis, PCs plasma cells, non-CE non chronic endometritis, HPF 
high-power field, SD standard deviation, IQR interquartile range, BMI body mass 
index, FSH follicle stimulate hormone, OPU ova pick up, EM endometrial, ASA 
anti-sperm antibody positive
Non-CE CE P value
N = 27 N = 26
Age (y), Mean ± SD 35.0 ± 3.30 36.2 ± 3.45 0.2
Gravidity, Median, IQR 0 (0–2) 0 (0–1) 0.23
Parity, Median, IQR 0 (0–0) 0 (0–1) 0.039
BMI (kg/m2), Median, IQR 21.4 (18.9–23.7) 21.8 (20.2–26.6) 0.24
Smoking habit (%) 0 0 1.00
FSH (mIU/mL), Median, IQR 8.1 (4.8–24) 9.1 (5–12.5) 0.2
Previous OPU cycles, Median 
IQR
1 (1–4) 1.5 (1–2.25) 0.72
EM thickness (mm), 
Mean ± SD
10.3 ± 1.60 10.5 ± 2.38 0.75
Rate of good blastocysts (%) 59.3 (16/27) 65.4 (17/26) 0.78
Infertility cause
 Tubal factor 5 10 0.14
 Ovarian factor 4 4 1
 Endometriosis 7 6 1
 ASA 0 0 1
 Fertilization failure 1 1 1
 Male factor 7 6 1
 Unexplained fertility 10 4 0.12
Pregnancy rate (%) 63.0 (17/27) 30.8 (8/26) 0.028
Live birth rate (%) 51.9 (14/27) 7.7 (2/26) 0.0007
Miscarriage rate (%) 17.7 (3/17) 75 (6/8) 0.0099
Table 2 Patients’ characteristics and  clinical outcomes 
when CE was defined as ≥ 2 PCs in 10 HPFs 
CE chronic endometritis, PCs plasma cells, non-CE non chronic endometritis, HPF 
high-power field, SD standard deviation, IQR interquartile range, BMI body mass 
index, FSH follicle stimulate hormone, OPU ova pick up, EM endometrial, ASA 
anti-sperm antibody positive
Non-CE CE P value
N = 34 N = 19
Age (y), Median, IQR 36 (32.5–37) 38 (35–39) 0.028
Gravidity, Median, IQR 0 (0–0.25) 0 (0–1) 0.13
Parity, Median, IQR 0 (0–1) 0 (0–1) 0.0023
BMI (kg/m2), Median, IQR 21.8 (19.6–24.1) 21.0 (20.1–25.9) 0.83
Smoking habit (%) 0 0 1
FSH (mIU/mL), Median, IQR 8.85 (7.4–9.7) 8.8 (7.4–10.3) 0.97
Previous OPU cycles, Median 
IQR
1.5 (1–4) 1 (1–2) 0.33
EM thickness (mm), 
Mean ± SD
10.5 ± 2.05 10.2 ± 1.95 0.55
Rate of good blastocysts (%) 61.2 (21/34) 63.1 (12/19) 0.99
Infertility cause
 Tubal factor 6 9 0.029
 Ovarian factor 5 3 1
 Endometriosis 8 5 1
 ASA 0 0 1
 Fertilization failure 1 1 1
 Male factor 11 2 0.10
 Unexplained fertility 11 3 0.33
Pregnancy rate (%) 58.8 (20/34) 26.3 (5/19) 0.043
Live birth rate (%) 44.1 (15/34) 5.3 (1/19) 0.0041
Miscarriage rate (%) 25 (5/20) 80 (4/5) 0.04
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rate and live birth rate of the non-CE group were high-
est when the diagnostic criterion for CE was the presence 
of ≥ 1 plasma cells in 10 HPFs. The pregnancy rate and 
live birth rate of the non-CE group decreased gradually 
as the minimum number of plasma cells in 10 HPFs for 
the diagnostic criterion for CE increased from ≥ 2 to ≥ 5. 
On the other hand, the miscarriage rate of the non-CE 
group was the lowest when the diagnostic criterion for 
CE was the presence of ≥ 1 plasma cells in 10 HPFs. All P 
values for the pregnancy rate, live birth rate, and miscar-
riage rate were the smallest when the diagnostic criterion 
of CE was the presence of ≥ 1 plasma cells in 10 HPFs. 
Their P values increased gradually as the minimum num-
ber of plasma cells in 10 HPFs for the diagnostic criterion 
for CE increased from ≥ 1 to ≥ 5. When the diagnostic 
criterion for CE was the presence of ≥ 5 plasma cells in 10 
HPFs, there were no significant differences in the preg-
nancy rates and live birth rates.
In the multivariate logistic regression analysis, CE was 
an explanatory variable negatively affecting the objective 
variable of live birth only when CE was diagnosed based 
on the presence of ≥ 1 or ≥ 2 plasma cells per 10 HPFs. In 
addition, in the evaluation of the ROC curve, the optimal 
cut-off was determined to be ≥ 1 plasma cell per 10 HPFs. 
Taken together, these findings suggest that CE should be 
diagnosed when ≥ 1 plasma cell is found among 10 HPFs, 
and CE had a detrimental effect on the clinical outcomes 
of in  vitro fertilization when it was diagnosed with this 
criterion.
In the present study, the live birth rate and miscarriage 
rate did differ among the three groups although there was 
no statistically difference in the pregnancy rate (Table 6). 
Table 3 Patients’ characteristics and  clinical outcomes 
when CE was defined as ≥ 3 PCs in 10 HPFs 
CE chronic endometritis, PCs plasma cells, non-CE non chronic endometritis, HPF 
high-power field, SD standard deviation, IQR interquartile range, BMI body mass 
index, FSH follicle stimulate hormone, OPU ova pick up, EM endometrial, ASA 
anti-sperm antibody positive
Non-CE CE P value
N = 39 N = 14
Age (y), Median, IQR 36 (33–37) 38 (37–39) 0.0051
Gravidity, Median, IQR 0 (0–0) 0.5 (0–2) 0.04
Parity, Median, IQR 0 (0–0) 0.5 (0–1) 0.0006
BMI (kg/m2), Median, IQR 21.9 (19.6–24.5) 20.9 (19.9–24.1) 0.54
Smoking habit (%) 0 0 1
FSH (mIU/mL), Median, IQR 8.6 (6.7–9.7) 9.05 (7.83–10.4) 0.18
Previous OPU cycles, Median 
IQR
1 (1–4) 1.5 (1–3.3) 0.93
EM thickness (mm), 
Mean ± SD
10.5 ± 2.0 10.0 ± 2.0 0.39
Rate of good blastocysts (%) 64.1 (25/39) 57.1 (8/14) 0.75
Infertility cause
 Tubal factor 10 5 0.50
 Ovarian factor 6 2 1
 Endometriosis 9 4 0.73
 ASA 0 0 1
 Fertilization failure 1 1 0.4
 Male factor 11 2 0.47
 Unexplained fertility 11 3 0.74
Pregnancy rate (%) 53.9 (21/39) 28.6 (4/14) 0.13
Live birth rate (%) 38.5 (15/39) 7.1 (1/14) 0.041
Miscarriage rate (%) 28.6 (6/21) 75 (3/4) 0.12
Table 4 Patients’ characteristics and  clinical outcomes 
when CE was defined as ≥ 5 PCs in 10 HPFs 
CE chronic endometritis, PCs plasma cells, non-CE non chronic endometritis, HPF 
high-power field, SD standard deviation, IQR interquartile range, BMI body mass 
index, FSH follicle stimulate hormone, OPU ova pick up, EM endometrial, ASA 
anti-sperm antibody positive
Non-CE CE P value
N = 42 N = 11
Age (y), Median, IQR 36 (33–37) 38 (37–39) 0.04
Gravidity, Median, IQR 0 (0–2) 0 (0–2) 0.15
Parity, Median, IQR 0 (0–1) 0 (0–2) 0.023
BMI (kg/m2), Median, IQR 21.8 (19.6–24.1) 20.9 (20.1–25.9) 0.90
Smoking habit (%) 0 0 1
FSH (mIU/mL), Median, IQR 8.7 (6.9–9.8) 9 (7.6–10.3) 0.42
Previous OPU cycles, Median 
IQR
1.5 (1–4) 1 (1–3) 0.46
EM thickness (mm), 
Mean ± SD
10.4 ± 2.0 10.2 ± 2.1 0.77
Rate of good blastocysts (%) 59.5 (25/42) 72.3 (8/11) 0.5
Infertility cause
 Tubal factor 11 4 0.71
 Ovarian factor 6 2 0.67
 Endometriosis 11 2 0.71
 ASA 0 0 1
 Fertilization failure 2 0 1
 Male factor 12 1 0.26
 Unexplained fertility 11 3 1
Pregnancy rate (%) 50 (15/42) 36.4 (4/11) 0.51
Live birth rate (%) 35.7 (15/42) 9.1 (1/11) 0.14
Miscarriage rate (%) 28.6 (6/21) 75 (3/4) 0.12
Table 5 A multivariate logistic regression analysis 
for  variables negatively affecting live birth in  each 
criterion
CE chronic endometritis, CI confidential interval, HPF high power field
Diagnostic criterion Variable Odds ratio 95% CI P value
 ≥ 1 plasma cells in 10 
HPFs
CE 0.081 0.010–0.625 0.016
 ≥ 2 plasma cells in 10 
HPFs
CE 0.064 0.004–0.928 0.044
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The live birth rates were higher in the patients with no 
plasma cells than in those with 1–4 or ≥ 5 plasma cells 
per 10 HPFs when compared between the two groups 
although there were no marked differences between the 
patients with 1–4 and ≥ 5 plasma cells per 10 HPFs with 
respect to these rates. The pregnancy rate and miscar-
riage rate did not differ between any combination of the 
3 groups (Table 6). This indicates that when plasma cells 
were detected, the live birth rate decreased in the same 
way, regardless of the number of plasma cells detected.
In studies based on the detection of plasma cells, the 
criteria were ≥ 1 plasma cell per section [10, 12], ≥ 1 
plasma cell in the stromal area among 10 HPFs [6], ≥ 5 
plasma cells in the stromal area among 20 HPFs [34], 
and ≥ 5 plasma cells in the stromal area among 10 HPFs 
[11], showing marked variety among studies. In these 
reports, the efficacy of antibiotics on the clinical out-
comes or the prevalence of CE was determined. However, 
in those studies, antibiotics could not be administered 
without establishing diagnostic criteria in advance, and 
the prevalence of CE could not be determined either 
without establishing diagnostic criteria in advance. Thus, 
this methodology interferes with the determination of CE 
criteria based on the clinical outcomes. Recently, a few 
retrospective studies have established diagnostic crite-
ria based on the clinical outcomes without the usage of 
antibiotics, even when CD138-positive cells were found 
in the endometrial stroma [36, 37]. In one study, CD138-
positive cells were counted, excluding positive cells in 
the lumen and glands, in patients with RIF. The results 
were expressed as the number of CD138 cells per section. 
Based on the ROC analysis, the optimal cut-off value was 
concluded to be 0.5 (sensitivity of 77.2% and specificity of 
52.5%) [37]. This result was similar to our own in that CE 
was diagnosed when even 1 plasma cell was found.
Another study determined the diagnostic criterion in 
patients undergoing in  vitro fertilization, including RIF. 
In that study, 30 HPFs were evaluated for each sample, 
resulting in a criterion of ≥ 5 CD138-positive cells in ≥ 1 
HPF [36]. This study asserted the importance of finding 
the accumulation of five or more plasma cells in a given 
area. This analysis was conducted based on a different 
point of view than our study.
However, it might be difficult to evaluate the effect 
of CE on implantation in the above-mentioned studies 
when control group includes RIF, since the pregnancy 
rate in patients with RIF will decrease in subsequent 
treatment cycles due to the presence of implantation fail-
ure causes other than CE.
The present study included patients undergoing IVF, 
but excluded patients with RIF, RPL, and causes of 
implantation failure when enrolled. This is the decisive 
difference between the present study and the previous 
studies. As a result, for such patients, we have proven 
that those with even one plasma cell in the endometrial 
stromal area should be diagnosed with CE because of 
their lower pregnancy rate and live birth rate. This result 
also indicates that the presence of CE adversely affects 
implantation, regardless of the presence of RIF, in the 
patients treated with IVF.
This study was a prospective study that excluded 
patients who were likely to affect implantation at the 
registration stage. A single blastocyst is transferred 
within three months after the diagnosis of CE in a uni-







Fig. 4 A receiver operating characteristic curve of the non-CE group 
for live birth. The sensitivity and specificity of the non-CE group for 
live birth were calculated for each of these diagnostic criteria, and 
a receiver operating characteristic (ROC) curve was drawn. The area 
under the curve of the ROC curve was 0.785. The optimal cut-off 
value was obtained when ≥ 1 plasma cell was found in 10 HPFs 
(sensitivity of 87.5% and specificity of 64.9%)
Table 6 Clinical outcomes among  three groups 
of the patients with 0, 1–4, and ≥ 5 plasma cells
*P < 0.05, Statistically significant difference was detected when comparing 
between the group of the patients with 0 plasma cell and the group of the 
patients with ≥ 5 plasma cells
**P < 0.01, Statistically significant difference was detected when comparing 
between the group of the patients with 0 plasma cell and the group of the 
patients with 1–4 plasma cells
Number of plasma 
cells
0 1–4  ≥ 5 P value
N = 27 N = 15 N = 11
Pregnancy rate (%) 63.0 (17/27) 33.3 (4/15) 36.4 (4/11) 0.057
Live birth rate (%) 51.9 (14/27)*,** 8.3 (1/15) 9.1 (1/11) 0.0022
Miscarriage rate (%) 17.6 (3/14) 75 (3/4) 75 (3/4) 0.049
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present study, three different analyses—the evalua-
tion of differences in clinical outcomes among the 
four criteria, a logistic regression analysis for the live 
birth rate and the determination of the optimal cut-off 
value using the ROC curve—indicated the same diag-
nostic criteria for the diagnosis of CE. These are the 
strengths of the present study.
However, several limitations associated with the pre-
sent study also warrant mention. First, the number of 
participants were relatively small compared with other 
studies, although the number of samples required for 
this prospective study was calculated based on the 
results of a similar retrospective clinical study con-
ducted previously.
Second, this study analyzed the clinical outcomes 
in the hormone replacement cycle using DYD. As a 
recent report suggested, the efficacy of the oral admin-
istration of DYD as luteal support in fresh embryo 
transfer is equivalent or superior to that of a progester-
one vaginal suppository [38–40]. However, the results 
of the present study may be limited by this hormone 
replacement cycle.
Third, due to ethical issues, the results of CE were 
disclosed to patients, and when desired, treatment 
was performed, such as the administration of antibiot-
ics. Patients who wished to be treated with antibiotics 
might have been potentially intractable cases, so the 
exclusion of these patients may have resulted in bias.
Now that the diagnostic criterion has been estab-
lished, our next research topic will be to determine 
whether or not the clinical outcomes of patients diag-
nosed with CE based on the diagnostic criterion are 
improved after these patients are cured, such as by 
treatment with antibiotics. It will be particularly nec-
essary to confirm whether or not the pregnancy con-
tinues to term following the successful treatment of 
CE.
Finally, various immunocompetent cells are present 
in the endometrium and are involved in the establish-
ment of pregnancy [41–44]. CE causes the abnormal 
distribution of immunocompetent cells in the endo-
metrium of implantation phase [45, 46]. Research is 
currently underway using the term “endometritis”, 
which is primarily caused by bacteria. In this sense, 
“impaired inflammatory state of the endometrium 
(IISE)” might be a more appropriate term than “endo-
metritis”, as it directly indicates “inflammation of the 
endometrium”, regardless of the cause [42, 43]. We may 
need to revise concepts, including terminology, with 
respect to research being conducted on inflammation 
in the uterus and the evaluation of its effect on fertil-
ity. We intend to explore this issue in a future study.
Conclusions
The present prospective study showed that the preg-
nancy rate, live birth rate and miscarriage rate of the 
non-CE group differed depending on the diagnostic 
criteria used for CE. Based on our evaluation of the 
differences in the pregnancy rate, live birth rate and 
miscarriage rate among the four criteria as well as the 
results of a logistic regression analysis for live birth and 
the optimal cut-off value analyzed based on the ROC 
curve, CE should be diagnosed in the presence of ≥ 1 
plasma cell per 10 HPFs. With this diagnostic criterion, 
it was shown that CE adversely affected the pregnancy 
rate and live birth rate in IVF, even in patients without 
evidence of RIF, RPL or diseases suspected of causing 
implantation failure.
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